Yellowstone Biosciences Ltd. has launched with a focus on soluble bispecific T-cell receptor (TCR)-based therapies for human leukocyte antigen (HLA) class II (HLA-II) targets in oncology.
Among the acquired mutations in the calreticulin (CALR) gene, both 52 bp deletion (del52) and 5 bp insertion (ins5) are among the most frequent and are linked to two different types of myeloproliferative neoplasms (MPNs).
During the basic science morning track on the last day of this year’s Annual Congress of the European Hematology Association (EHA), the attention was focused on oncogenic transcription factors and complexes considered turning points within the acute myeloid leukemia (AML) arena.
Scientists at Chungnam National University assessed the role of estrogen-related receptor α (ERRα) in the context of acute myeloid leukemia (AML). First, it was demonstrated that ERRα expression levels were increased in bone marrow of patients with AML as compared to normal control patients, and that patient survival was significantly correlated with ERRα expression.
Researchers from Lund University presented data from a study that aimed to identify novel targets for immunotherapy in acute myeloid leukemia (AML). To identify differentially expressed cell surface proteins in the primitive CD34+CD38- cell populations, an arrayed antibody screen was performed on primary bone marrow samples from patients with AML as well as healthy donors.
The first oral session in the acute myeloid leukemia (AML) translational research track of June 15, was given by Eliza Yankova, from the University of Cambridge, who presented collaborative studies done together with Storm Therapeutics Ltd. outlining pharmacological inhibition of METTL1 as a therapeutic strategy in AML treatment.
The c-MYB oncogene plays an important role in hematopoietic cell differentiation and proliferation. Dysregulation of MYB downstream effector signaling is thought to be behind these abnormalities by modulation of genes such as BCL2, MYC or FLT3, and as such an attractive therapeutic target for acute myeloid leukemia (AML).
Bivictrix Therapeutics plc’s BVX-001, a first-in-class Bi-Cygni bispecific antibody-drug conjugate (ADC) for the treatment of acute myeloid leukemia (AML), has demonstrated a favorable toxicity profile in an industry standard toxicology model.
Even though the treatment options that exist for acute myeloid leukemia (AML) are growing, the clinical outcome of patients is still unfavorable. In AML dysregulation of the tyrosine kinase receptors, including RAS, RAF, MEK and ERK, and of the Aurora kinase family (AURK) exists, are both tied to AML development and progression.
Bluesphere Bio Inc. has received FDA clearance of its IND application for BSB-1001 for patients with relapsed or refractory acute myeloid leukemia (AML), acute lymphocytic leukemia and myelodysplastic syndromes, in conjunction with allogeneic hematopoietic stem cell transplantation (alloHSCT).
